Pfizer Inc. EBITDA for the Trailing 12 Months (TTM) ending March 29, 2025: USD 17.23 B

Pfizer Inc. EBITDA is USD 17.23 B for the Trailing 12 Months (TTM) ending March 29, 2025, a 131.97% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Pfizer Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 7.43 B, a -80.73% change year over year.
  • Pfizer Inc. EBITDA for the Trailing 12 Months (TTM) ending April 02, 2023 was USD 38.55 B, a 13.03% change year over year.
  • Pfizer Inc. EBITDA for the Trailing 12 Months (TTM) ending April 03, 2022 was USD 34.10 B, a 140.91% change year over year.
  • Pfizer Inc. EBITDA for the Trailing 12 Months (TTM) ending April 04, 2021 was USD 14.16 B, a -39.59% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)